Sangivamycin (OyaGen)

N/A

Report date: 2024/04/30 17:13:27

Base Information

Drug NameSangivamycin (OyaGen)
Drug Alias Nameaka sangivamycin (OyaGen)Oya1OYA-1TNX-3500
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C inhibitorsVirus replication inhibitors
TargetsProtein kinase C
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hemorrhagic Fever, Ebola
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOyaGen IncNational Institute Of Allergy And Infectious Diseases (Niaid)National Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesOyaGen IncTonix Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Hemorrhagic Fever, Ebola
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia